Vycor Medical Posts Third-Quarter Results as Clinical Evidence for Its Brain Access System Grows to 54 Peer-Reviewed Papers
Found this article helpful?
Share it with your network and spread the knowledge!

Vycor Medical, Inc., the Boca Raton-based company whose ViewSite Brain Access System is used in more than 350 U.S. hospitals, reported financial results for the three and nine months ended September 30, 2026, pairing a revenue decline against a strong prior-year comparison with continued expansion of the clinical evidence behind its neurosurgical device. The results, announced through NEWMEDIAWIRE, offer a window into how a small, publicly traded medical device maker is building credibility in a market where published outcomes data can matter as much as quarterly sales.
For the third quarter, the company reported total revenue of $414,895, a 19% decrease from the 2025 period. The Vycor Medical division, which makes the ViewSite Brain Access System, generated $402,048, down $90,054, or 18%. Vycor attributed much of the decline to unusually high U.S. sales in 2025, when new hospitals came on board and some existing hospitals placed bulk orders. International sales, which rose for the quarter, can be lumpy as large orders fall in different periods. Gross profit was $353,017, a 22% decrease, with margins of 85% in 2026 and 88% in 2025. Operating profit was $27,424, compared with $32,085 a year earlier, and non-GAAP operating profit was $43,011 versus $60,162.
For the nine months, revenue was $1,291,699, an 11% decrease. The Vycor Medical division contributed $1,243,713, down $148,697, while gross profit was $1,072,615 at an 83% margin. Operating profit for the nine months rose to $80,083 from $70,425, and non-GAAP operating profit was $125,751 compared with $166,262. The NovaVision division, still in development, generated $12,847 for the quarter, a 41% increase, and $47,986 for the nine months, an 11% increase.
The strategic significance lies in the clinical pipeline. Four new peer-reviewed studies on the ViewSite Brain Access System were published during 2026, bringing the total to 54 peer-reviewed clinical papers plus 14 other clinical papers. One pediatric tumor case study highlighted integrating neuro-navigation with the system as a paramount strategy for surgical resection. A 23-patient retrospective study found significantly fewer new neurological deficits with the tubular retractor compared with traditional blade retractors, implying safer tumor resection. A 29-patient study of posterior fossa metastases concluded that minimally invasive tubular resection enables effective decompression with low cerebrospinal fluid diversion rates. A fourth paper documented two intracerebral hemorrhage evacuation cases in Japan using the system with an exoscope. An overview is available through the VBAS Video.
For Texas, a state with major neurosurgical centers and a growing population of stroke and brain-injury patients, the evidence matters. Fewer neurological deficits and shorter recovery times translate into lower hospital costs and better outcomes. NovaVision's therapies, including the FDA-cleared Visual Restoration Therapy, address vision loss after stroke or brain injury; the NovaVision Video outlines the programs. The company notes NovaVision still requires significant development to address its market potential.
Vycor's results underscore a familiar challenge for device innovators: revenue can swing with hospital purchasing cycles, but durable clinical validation supports adoption. Additional detail is available at www.vycormedical.com and www.vycorvbas.com, and NovaVision information is at www.novavision.com. The full release appears on www.newmediawire.com. For Texas hospitals and the medical device sector, the takeaway is that evidence generation remains a central competitive lever in minimally invasive neurosurgery.
